請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40354
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃德富(Tur-Fu Hung) | |
dc.contributor.author | Szu-Ying Wu | en |
dc.contributor.author | 吳思瑩 | zh_TW |
dc.date.accessioned | 2021-06-14T16:45:32Z | - |
dc.date.available | 2016-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-12 | |
dc.identifier.citation | Adam, F., A. Kauskot, et al. (2010). 'Platelet JNK1 is involved in secretion and thrombus formation.' Blood 115(20): 4083-92.
Adam, F., A. Kauskot, et al. (2008). 'Mitogen-activated protein kinases in hemostasis and thrombosis.' J Thromb Haemost 6(12): 2007-16. Aid, S. and F. Bosetti (2011). 'Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.' Biochimie 93(1): 46-51. Aid, S., R. Langenbach, et al. (2008). 'Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2.' J Neuroinflammation 5: 17. Aid, S., A. C. Silva, et al. (2010). 'Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced blood-brain barrier disruption through matrix metalloproteinase activity.' J Cereb Blood Flow Metab 30(2): 370-80. Akbar, H., J. Kim, et al. (2007). 'Genetic and pharmacologic evidence that Rac1 GTPase is involved in regulation of platelet secretion and aggregation.' J Thromb Haemost 5(8): 1747-55. Alevriadou, B. R., J. L. Moake, et al. (1993). 'Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets.' Blood 81(5): 1263-76. Arai, I., H. Hirose, et al. (1985). 'Possible involvement of non-steroidal anti-inflammatory drugs in vagal-mediated gastric acid secretion in rats.' Jpn J Pharmacol 37(1): 91-9. Asazuma, N., Y. Ozaki, et al. (1997). 'Glycoprotein Ib-von Willebrand factor interactions activate tyrosine kinases in human platelets.' Blood 90(12): 4789-98. Atkinson, B. T., G. E. Jarvis, et al. (2003). 'Activation of GPVI by collagen is regulated by alpha2beta1 and secondary mediators.' J Thromb Haemost 1(6): 1278-87. Barkalow, K. L., H. Falet, et al. (2003). 'Role for phosphoinositide 3-kinase in Fc gamma RIIA-induced platelet shape change.' Am J Physiol Cell Physiol 285(4): C797-805. Bergmeier, W. and L. Stefanini (2009). 'Novel molecules in calcium signaling in platelets.' J Thromb Haemost 7 Suppl 1: 187-90. Born, G. V. and M. J. Cross (1963). 'The Aggregation of Blood Platelets.' J Physiol 168: 178-95. Borsch-Haubold, A. G., R. M. Kramer, et al. (1995). 'Cytosolic phospholipase A2 is phosphorylated in collagen- and thrombin-stimulated human platelets independent of protein kinase C and mitogen-activated protein kinase.' J Biol Chem 270(43): 25885-92. Brenneis, C., T. J. Maier, et al. (2006). 'Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition.' FASEB J 20(9): 1352-60. Bugaud, F., F. Nadal-Wollbold, et al. (1999). 'Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets.' Blood 94(11): 3800-5. Campbell, C. L., S. Smyth, et al. (2007). 'Aspirin dose for the prevention of cardiovascular disease: a systematic review.' JAMA 297(18): 2018-24. Candelario-Jalil, E., S. Taheri, et al. (2007). 'Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat.' J Pharmacol Exp Ther 323(2): 488-98. Chang, M. C., H. K. Lin, et al. (1998). 'Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox.' Blood 91(5): 1582-9. Choi, S. H., S. Aid, et al. (2009). 'The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.' Trends Pharmacol Sci 30(4): 174-81. Choi, S. H., R. Langenbach, et al. (2008). 'Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury.' FASEB J 22(5): 1491-501. Chung, C. H., H. C. Peng, et al. (2001). 'Aggretin, a C-type lectin protein, induces platelet aggregation via integrin alpha(2)beta(1) and GPIb in a phosphatidylinositol 3-kinase independent pathway.' Biochem Biophys Res Commun 285(3): 689-95. Clemetson, K. J. and J. M. Clemetson (2001). 'Platelet collagen receptors.' Thromb Haemost 86(1): 189-97. Cohen, M. M. and W. C. MacDonald (1982). 'Mechanism of aspirin injury to human gastroduodenal mucosa.' Prostaglandins Leukot Med 9(2): 241-55. Cole, A. T., N. Hudson, et al. (1999). 'Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?' Aliment Pharmacol Ther 13(2): 187-93. Coller, B. S. and S. J. Shattil (2008). 'The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.' Blood 112(8): 3011-25. Coughlin, S. R. (1999). 'How the protease thrombin talks to cells.' Proc Natl Acad Sci U S A 96(20): 11023-7. Darling, R. L., J. J. Romero, et al. (2004). 'The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice.' Gastroenterology 127(1): 94-104. Dejana, E., S. Villa, et al. (1982). 'Bleeding time in rats: a comparison of different experimental conditions.' Thromb Haemost 48(1): 108-11. Djellas, Y., J. M. Manganello, et al. (1999). 'Identification of Galpha13 as one of the G-proteins that couple to human platelet thromboxane A2 receptors.' J Biol Chem 274(20): 14325-30. Dogne, J. M., J. Hanson, et al. (2004). 'Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.' J Pharmacol Exp Ther 309(2): 498-505. Du, X. (2007). 'Signaling and regulation of the platelet glycoprotein Ib-IX-V complex.' Curr Opin Hematol 14(3): 262-9. Falati, S., C. E. Edmead, et al. (1999). 'Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor gamma-chain, Fyn, and Lyn to activate human platelets.' Blood 94(5): 1648-56. Fitzgerald, D. J., L. Roy, et al. (1986). 'Platelet activation in unstable coronary disease.' N Engl J Med 315(16): 983-9. Furman, M. I., L. A. Krueger, et al. (2004). 'Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.' J Am Coll Cardiol 43(12): 2319-25. Gachet, C. (2006). 'Regulation of platelet functions by P2 receptors.' Annu Rev Pharmacol Toxicol 46: 277-300. Gale, A. J. (2011). 'Continuing education course #2: current understanding of hemostasis.' Toxicol Pathol 39(1): 273-80. Garcia-Bueno, B., J. Serrats, et al. (2009). 'Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli.' J Neurosci 29(41): 12970-81. Garcia, A., H. Shankar, et al. (2007). 'Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets.' Biochem J 404(2): 299-308. Gibbins, J. M. (2004). 'Platelet adhesion signalling and the regulation of thrombus formation.' J Cell Sci 117(Pt 16): 3415-25. Hassock, S. R., M. X. Zhu, et al. (2002). 'Expression and role of TRPC proteins in human platelets: evidence that TRPC6 forms the store-independent calcium entry channel.' Blood 100(8): 2801-11. Hoozemans, J. J., A. J. Rozemuller, et al. (2001). 'Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain.' Acta Neuropathol 101(1): 2-8. Huang, J. S., L. Dong, et al. (2007). 'Signaling through G(alpha)13 switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion.' J Biol Chem 282(14): 10210-22. Italiano, J. E., Jr., J. L. Richardson, et al. (2008). 'Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released.' Blood 111(3): 1227-33. Jackson, S. P., W. S. Nesbitt, et al. (2003). 'Signaling events underlying thrombus formation.' J Thromb Haemost 1(7): 1602-12. Jaramillo, E., S. Mardh, et al. (1989). 'The effect of arachidonic acid and its metabolites on acid production in isolated human parietal cells.' Scand J Gastroenterol 24(10): 1231-7. Jeong, H. S., J. H. Kim, et al. (2010). 'Induction of cell growth arrest and apoptotic cell death in human breast cancer MCF-7 cells by the COX-1 inhibitor FR122047.' Oncol Rep 24(2): 351-6. Jin, Y. R., K. A. Hwang, et al. (2004). 'Antiplatelet and antithrombotic activities of CP201, a newly synthesized 1,4-naphthoquinone derivative.' Vascul Pharmacol 41(1): 35-41. Kakkar, R., R. V. Raju, et al. (1996). 'Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl.' Life Sci 59(21): PL337-41. Kato, K., T. Kanaji, et al. (2003). 'The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion.' Blood 102(5): 1701-7. Kis, B., J. A. Snipes, et al. (2005). 'Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties.' J Pharmacol Exp Ther 315(1): 1-7. Knezevic, I., C. Borg, et al. (1993). 'Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors.' J Biol Chem 268(34): 26011-7. Konopatskaya, O., K. Gilio, et al. (2009). 'PKCalpha regulates platelet granule secretion and thrombus formation in mice.' J Clin Invest 119(2): 399-407. Kramer, R. M., E. F. Roberts, et al. (1995). 'Thrombin induces activation of p38 MAP kinase in human platelets.' J Biol Chem 270(46): 27395-8. Kyriakis, J. M. and J. Avruch (2001). 'Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.' Physiol Rev 81(2): 807-69. Leslie, M. (2010). 'Cell biology. Beyond clotting: the powers of platelets.' Science 328(5978): 562-4. Li, W., Z. L. Ji, et al. (2010). 'Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice.' Med Oncol 27(1): 98-104. Li, W., J. Wang, et al. (2011). 'Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.' Int J Mol Sci 12(1): 668-81. Li, Z., M. K. Delaney, et al. (2010). 'Signaling during platelet adhesion and activation.' Arterioscler Thromb Vasc Biol 30(12): 2341-9. Li, Z., X. Xi, et al. (2003). 'A stimulatory role for cGMP-dependent protein kinase in platelet activation.' Cell 112(1): 77-86. Li, Z., G. Zhang, et al. (2004). 'A platelet secretion pathway mediated by cGMP-dependent protein kinase.' J Biol Chem 279(41): 42469-75. Lian, L., Y. Wang, et al. (2009). 'Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis.' Blood 113(15): 3577-84. Lincoff, A. M. (2003). 'Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade.' Circulation 107(11): 1556-9. Lopez, J. A. and J. F. Dong (1997). 'Structure and function of the glycoprotein Ib-IX-V complex.' Curr Opin Hematol 4(5): 323-9. Marshall, S. J., N. Asazuma, et al. (2002). 'Glycoprotein IIb-IIIa-dependent aggregation by glycoprotein Ibalpha is reinforced by a Src family kinase inhibitor (PP1)-sensitive signalling pathway.' Biochem J 361(Pt 2): 297-305. Massberg, S., M. Gawaz, et al. (2003). 'A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo.' J Exp Med 197(1): 41-9. McColl, B. W., N. J. Rothwell, et al. (2007). 'Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms.' J Neurosci 27(16): 4403-12. Michelson, A. D. (2010). 'Antiplatelet therapies for the treatment of cardiovascular disease.' Nat Rev Drug Discov 9(2): 154-69. Moake, J. L., N. A. Turner, et al. (1988). 'Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin.' Blood 71(5): 1366-74. Morise, Z., D. N. Granger, et al. (1999). 'Indomethacin induced gastropathy in CD18, intercellular adhesion molecule 1, or P-selectin deficient mice.' Gut 45(4): 523-8. Munday, A. D., M. C. Berndt, et al. (2000). 'Phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein Ib-IX-V complex and 14-3-3zeta.' Blood 96(2): 577-84. Mustard, J. F., D. W. Perry, et al. (1972). 'Preparation of suspensions of washed platelets from humans.' Br J Haematol 22(2): 193-204. Nakahata, N. (2008). 'Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology.' Pharmacol Ther 118(1): 18-35. Nurden, A. T., P. Nurden, et al. (2008). 'Platelets and wound healing.' Front Biosci 13: 3532-48. Offermanns, S. (2006). 'Activation of platelet function through G protein-coupled receptors.' Circ Res 99(12): 1293-304. Ohlmann, P., K. L. Laugwitz, et al. (1995). 'The human platelet ADP receptor activates Gi2 proteins.' Biochem J 312 ( Pt 3): 775-9. Ozaki, Y., K. Satoh, et al. (1995). 'Protein tyrosine phosphorylation in human platelets induced by interaction between glycoprotein Ib and von Willebrand factor.' Biochim Biophys Acta 1243(3): 482-8. Papkoff, J., R. H. Chen, et al. (1994). 'p42 mitogen-activated protein kinase and p90 ribosomal S6 kinase are selectively phosphorylated and activated during thrombin-induced platelet activation and aggregation.' Mol Cell Biol 14(1): 463-72. Parise, L. V., D. L. Venton, et al. (1984). 'Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.' J Pharmacol Exp Ther 228(1): 240-4. Pasquet, J. M., R. Bobe, et al. (1999). 'A collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-kinase in human platelets.' Biochem J 342 ( Pt 1): 171-7. Patrono, C. (2006). 'The PGH-synthase system and isozyme-selective inhibition.' J Cardiovasc Pharmacol 47 Suppl 1: S1-6. Patrono, C., B. Coller, et al. (2004). 'Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.' Chest 126(3 Suppl): 234S-264S. Patrono, C., L. A. Garcia Rodriguez, et al. (2005). 'Low-dose aspirin for the prevention of atherothrombosis.' N Engl J Med 353(22): 2373-83. Pearson, G., F. Robinson, et al. (2001). 'Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions.' Endocr Rev 22(2): 153-83. Perrone, M. G., A. Scilimati, et al. (2010). 'Selective COX-1 inhibition: A therapeutic target to be reconsidered.' Curr Med Chem 17(32): 3769-805. Phillis, J. W., L. A. Horrocks, et al. (2006). 'Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders.' Brain Res Rev 52(2): 201-43. Poligone, B. and A. S. Baldwin (2001). 'Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins.' J Biol Chem 276(42): 38658-64. Razdan, K., J. D. Hellums, et al. (1994). 'Shear-stress-induced von Willebrand factor binding to platelets causes the activation of tyrosine kinase(s).' Biochem J 302 ( Pt 3): 681-6. Reed, G. L., M. L. Fitzgerald, et al. (2000). 'Molecular mechanisms of platelet exocytosis: insights into the 'secrete' life of thrombocytes.' Blood 96(10): 3334-42. Ren, Q., S. Ye, et al. (2008). 'The platelet release reaction: just when you thought platelet secretion was simple.' Curr Opin Hematol 15(5): 537-41. Rho, M. C., N. Nakahata, et al. (1997). 'Involvement of phospholipase C-gamma2 in activation of mitogen-activated protein kinase and phospholipase A2 by zooxanthellatoxin-A in rabbit platelets.' J Pharmacol Exp Ther 282(1): 496-504. Rink, T. J. and S. O. Sage (1990). 'Calcium signaling in human platelets.' Annu Rev Physiol 52: 431-49. Roffi, M., D. P. Chew, et al. (2001). 'Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.' Circulation 104(23): 2767-71. Ruggeri, Z. M. (2002). 'Platelets in atherothrombosis.' Nat Med 8(11): 1227-34. Savage, B., E. Saldivar, et al. (1996). 'Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.' Cell 84(2): 289-97. Schulte, V., T. Rabie, et al. (2003). 'Targeting of the collagen-binding site on glycoprotein VI is not essential for in vivo depletion of the receptor.' Blood 101(10): 3948-52. Schulze, H. and R. A. Shivdasani (2005). 'Mechanisms of thrombopoiesis.' J Thromb Haemost 3(8): 1717-24. Shattil, S. J., C. Kim, et al. 'The final steps of integrin activation: the end game.' Nat Rev Mol Cell Biol 11(4): 288-300. Shattil, S. J. and P. J. Newman (2004). 'Integrins: dynamic scaffolds for adhesion and signaling in platelets.' Blood 104(6): 1606-15. Skaper, S. D. (2007). 'The brain as a target for inflammatory processes and neuroprotective strategies.' Ann N Y Acad Sci 1122: 23-34. Smith, C. J., Y. Zhang, et al. (1998). 'Pharmacological analysis of cyclooxygenase-1 in inflammation.' Proc Natl Acad Sci U S A 95(22): 13313-8. Smith, W. L. and R. Langenbach (2001). 'Why there are two cyclooxygenase isozymes.' J Clin Invest 107(12): 1491-5. Stojanovic, A., J. A. Marjanovic, et al. (2006). 'A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation.' J Biol Chem 281(24): 16333-9. Sullam, P. M., W. C. Hyun, et al. (1998). 'Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor FcgammaRIIA on the platelet plasma membrane.' J Biol Chem 273(9): 5331-6. Tanaka, T., Y. Fukuta, et al. (1998). 'Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist.' Eur J Pharmacol 357(1): 53-60. Thomas, D. W., R. B. Mannon, et al. (1998). 'Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.' J Clin Invest 102(11): 1994-2001. Trier, D. A., K. D. Gank, et al. (2008). 'Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release.' Infect Immun 76(12): 5706-13. van Willigen, G., G. Gorter, et al. (2000). 'Thrombopoietin increases platelet sensitivity to alpha-thrombin via activation of the ERK2-cPLA2 pathway.' Thromb Haemost 83(4): 610-6. Wang, H., I. M. Hitron, et al. (2005). 'Synaptic and vascular associations of neurons containing cyclooxygenase-2 and nitric oxide synthase in rat somatosensory cortex.' Cereb Cortex 15(8): 1250-60. Weng, Z., D. Li, et al. 'PTEN regulates collagen-induced platelet activation.' Blood 116(14): 2579-81. Wu, W. K., J. J. Sung, et al. (2009). 'Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells.' Biochem Biophys Res Commun 382(1): 79-84. Wu, Y., K. Suzuki-Inoue, et al. (2001). 'Role of Fc receptor gamma-chain in platelet glycoprotein Ib-mediated signaling.' Blood 97(12): 3836-45. Xiang, B., G. Zhang, et al. (2010). 'A G(i) -independent mechanism mediating Akt phosphorylation in platelets.' J Thromb Haemost 8(9): 2032-41. Yap, C. L., S. C. Hughan, et al. (2000). 'Synergistic adhesive interactions and signaling mechanisms operating between platelet glycoprotein Ib/IX and integrin alpha IIbbeta 3. Studies in human platelets ans transfected Chinese hamster ovary cells.' J Biol Chem 275(52): 41377-88. Yermakova, A. V., J. Rollins, et al. (1999). 'Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons.' J Neuropathol Exp Neurol 58(11): 1135-46. Yu, I. S., S. R. Lin, et al. (2004). 'TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death.' Blood 104(1): 135-42. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40354 | - |
dc.description.abstract | 異常的血小板活化對於血栓生成是相當關鍵的一個步驟。因此,許多研究及臨床試驗指出,抗血小板製劑有益於於預防和治療栓塞性的心血管疾病 (例如:心肌梗塞及中風)。血管受傷後導致內皮下基質曝露 (例如:collagen 及vWF),循環中血小板因而有機會和它們接觸 (即adhesion),初始不穩定的接合(tethering)使得血小板在內皮上基質滾動 (rolling),導致血小板表面受體有更多機會和基質接觸,而產生比較穩固的結合,經由受體下方一連串的訊息傳遞終使血小板被活化(activation)、產生凝集(aggregation)最終是血栓塊(thrombus)生成。然而,目前使用的抗血小板藥物仍有許多限制(例如會增加出血風險、有抗藥性或無法口服等),因此開發新的抗血小板藥物有其必要性。
經由一系列的化合物篩選,我們發現化合物Than40具抑制人類血小板凝集的活性,並且在活性測試所使用濃度下,不影響細胞膜完整性。本篇論文主要在探討其抗血小板之機轉。在人類血小板懸浮液中,Than40呈濃度相關性的抑制由Collagen 及AA引起的血小板凝集,其IC50分別為6.85 ± 0.31 nM和51.05 ± 2.51 nM。此外,Than40也呈濃度相關性抑制由collagen和AA引起的P-selectin 表現量及thromboxane B2生成。在酵素活性分析方面,Than40主要呈濃度相關性抑制COX-1酵素活性(IC50為50.4nM),於10 uM下亦會減少TXS活性,但對於COX-2及PLC影響較小。在訊息傳遞方面,Than40呈時間相關性地抑制collagen引起的Fyn、Syk、Akt、ERK1/2及p38的磷酸化;然而,對PI3K、cSrc、JNK1/2/3之影響則不明顯。從酵素活性分析及訊息傳遞的結果,我們推測Than40經由抑制GP (主要是GPVI)下游的訊息傳遞分子,而干擾collagen引起的血小板活化及凝集;然而,Than40也能直接抑制COX-1酵素活性,而減少AA引起的血小板活化反應。在動物實驗中,Than40呈濃度相關性抑制collagen引起ICR小鼠富含血小板血漿(PRP)之血小板凝集 (IC50為22.48 uM)。進一步將Than40於尾靜脈注射1 ug/g,亦能明顯降低ICR小鼠的血小板凝集能力及有效抑制螢光素前處理小鼠之腸繫膜小靜脈血栓生成而不會明顯影響尾巴出血程度及血小板數。另一方面,當口服投予3 ug/g,Than40能抑制血小板凝集而不會引起急性胃部之損傷,顯示其為口服有效且安全之抗血栓藥物。綜合上述結果,Than40於體內及體外實驗皆呈現強效抑制血小板之活性,此化合物可做為抗血栓藥物之優勢化設計和研發。 | zh_TW |
dc.description.abstract | It is well-known that abnormal platelet activation is a key step in thrombogenesis. Therefore, antiplatelet agents have beneficial therapeutic effects in treating or preventing cardiovascular disease (such as myocardiac infarction and stroke). Upon blood vessel injury, platelets adhere to exposed extracellular matrix rapidly, such as collagen and von Willebrand factor, triggering sequential events, including tethering and rolling, platelet activation and platelet aggregation. However, novel antiplatelet agents with less side effects are still needed. We screened a series of synthetic compounds and found that Than40, a derivative of compound 5250, possesses concentration-dependent inhibition on platelet aggregation of washed human platelets induced by collagen (IC50=6.85 ± 0.31 nM) and arachidonic acid (IC50=51.05 ± 2.51 nM). We excluded its cytotoxicity by LDH release assay In addition, Than40 inhibited P-selectin expression and TXB2 formation induced by collagen or AA in a concentraion-dependent manner. In the enzyme activity assay, we found that Than40 primarily inhibited human platelet COX-1 in a concentration-dependent manner (IC50=50.4 nM) and secondarily inhibited TXS activity (at 10 uM), whereas it had little effect on enzyme activity of COX-2 and PLC. In the western blotting assay, Than40 inhibited collagen-induced phosphorylation of Fyn, Syk, Akt, ERK1/2 and p38 in a time-dependent manner, but phosphorylations of PI3K, cSrc and JNK1/2/3 were not affected. Therefore, we suppose that the suppression of GPVI downstream signaling transduction pathway may be responsible for the inhibitory effect of Than40 on collagen-induced platelet activation and aggregation, whereas the COX-1 inhibitory activity may contribute to the attenuated AA-induced ones. On the other hand, Than40 concentraion-dependently inhibited platelet aggregation of mice PRP induced by collagen (IC50=22.48 uM), which was about 100 folds higher than human PRP. When intravenously administered to mice (1ug/g), it impaired platelet aggregation of PRP caused by collagen. Furthermore, intravenously administered Than40 (1 ug/g) inhibited thrombus occlusion of the irradiated mesenteric vessels of fluorescein-pretreated mice with little impact on tail bleeding time and platelet counts. Upon oral administration of Than40 (3 ug/g), it exerted potent antiplatelet activity whereas it did not cause gastric lesions, implying that it is an orally active and safe antithrombotic agent.
Taken together, these results indicate that Than40 has potent antiplatelet activity both in vivo and ex vivo, suggesting that it may be an attractive lead compound for developing antithrombotic agents. | en |
dc.description.provenance | Made available in DSpace on 2021-06-14T16:45:32Z (GMT). No. of bitstreams: 1 ntu-100-R98443010-1.pdf: 4668784 bytes, checksum: a3280af1e106e9f0a2224dae767e4ec8 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 中文摘要………………………………………………………………………i
Abstract………………………………………………………………………………iii Abbreviation table…………………………………………………………………….v Chapter 1 Introduction…………………………………………………………….…..1 1.1 Roles of platelets………………………………………………………..1 1.2 Arterial thrombosis and cardiovascular disease…………………….......2 1.3 General mechanism of platelet activation………………………….…...2 1.4 Adhesion receptor-mediated platelet activation and signaling…………5 1.4.1 Collagen-induced platelet signaling……………………………....5 1.4.2 G-protein-coupled receptors (GPCR)-mediated signaling………..8 1.4.3 Integrin signaling……………………………………………….....9 1.4.4 Calcium signaling………………………………………………..10 1.4.5 Signaling leads to the granule secretion and secretion-dependant signal amplification……………………...…………………………….10 1.5 MAPK………………………………………………………………….11 1.6 Cylooxygenase (prostaglandin G/H synthase)………………………...12 1.7 The cPLA2-COX1-TXA2 pathway ……………………………………14 1.8 Current antiplatelet therapy and their limitations……………………..15 1.9 Structure activity of Than40 backbone………………………………..16 1.10 Aim of this study……………………………………………………..17 Chapter 2 Materials and methods………………………………………………….....29 2.1 Reagents and animals………………………………………………….29 2.2 Preparation of washed human platelets and platelet-rich plasma……..30 2.3 Measurement of platelet aggregation…………………...……………..31 2.4 LDH assay……………………………………………………………..31 2.5 Flow cytometric analysis of P-selectin expression……………………32 2.6 Measurement of TXB2 formation……………………………………..32 2.7 Biochemical assays of COX-1,COX-2, PLC and TXS activities……..33 2.8 Western blotting and immunoprecipitation…………………………....33 2.9 In vitro and ex vivo mouse platelet aggregation……………………….34 2.10 Fluorescein sodium-induced platelet thrombus formation in mesenteric venules of mice…………………………………………………….....35 2.11 Tail bleeding time in mice……………………………………………36 2.12 Acute gastric ulcer assay……………………………………………..36 2.13 Statistic analysis………………………………….…………………..36 Chapter 3 Results…………………………………………………………………….38 3.1 Effect of Than40 on platelet aggregation……………………………...38 3.2 Effect of Than40 on platelet LDH release…………………………….39 3.3 Effect of Than40 on arachidonic acid- and collagen-induced granule secretion and TXB2 formation in washed human platelet………….….….39 3.4 Effect of Than40 on COX-1, COX-2, TXS, and PLC activity………..40 3.5 Effect of Than40 on collagen downstream signaling……………...….40 3.6 Effect of Than40 on mice platelet aggregation of PRP……………….41 3.7 Effect of Than40 on in vivo thrombosis in a mouse model…………...42 3.8 Effect of Than40 on bleeding time and platelet counts……………….42 3.9 Effect of Than40 on gastric lesions…………………………………...43 Chapter 4 Discussion………………………………………………………………....66 Chapter 5 Conclusion and perspective………………………………………….……83 Reference……………………………………………………………………….…….87 | |
dc.language.iso | en | |
dc.title | 化合物Than40抑制血小板凝集作用及機轉之探討 | zh_TW |
dc.title | The antiplatelet effects and mechanisms of Than40 | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鄧哲明(Che-Ming Teng),楊春茂(Chuen-Mao Yang),顏茂雄(Mao-Hsiung Yen),吳文彬(Wen-bin Wu) | |
dc.subject.keyword | 抑制血小板凝集, | zh_TW |
dc.subject.keyword | antiplatelet effects, | en |
dc.relation.page | 102 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 4.56 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。